Patents Assigned to Hydra Biosciences
  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20250034143
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: February 21, 2024
    Publication date: January 30, 2025
    Applicant: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • PHARMACEUTICAL COMPOSITION COMPRISING 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
    Publication number: 20240261290
    Abstract: The present invention relates to a novel solid oral pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1H-purine-2,6-dione (Compound 1) as pharmaceutically active compound, a method for preparing the same and its use as a medicament. The novel solid oral pharmaceutical composition comprises Compound 1, a sugar alcohol and at least one further pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 6, 2024
    Publication date: August 8, 2024
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Hans-Juergen Martin, Eva Epple, Thomas Hennes, Ragna Saila Maria Hoffmann, Kerstin Julia Schaefer, Claudia Weiss
  • PROCESS FOR THE PREPARATION OF 7-(4-CHLOROBENZYL)-1-(3-HYDROXYPROPYL)-3-METHYL-8-(3-(TRIFLUOROMETHOXY)-PHENOXY)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE
    Publication number: 20240208976
    Abstract: The present invention relates to a novel process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)phenoxy)-3,7-dihydro-1H-purine-2,6-dione (compound (I)):
    Type: Application
    Filed: December 20, 2023
    Publication date: June 27, 2024
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Martin Butschies, Juergen Daeubler, Julia Feile, Annika Gille, Jannik Hahn, Alexander Haydl, Guenther Huchler, Christoph Kressierer, Josef Mesaki Landu, Sue Lauterbach, Zeno Andreas Leuter, Huayu Li, Jon Charles Lorenz, Markus Ostermeier, Michael Pangerl, Hartmut Schmidt, Sascha Wagner, Uwe Wallmen, Michael Wedel, Jiang-Ping Wu, Ewa Zimny
  • Substituted xanthines and methods of use thereof
    Patent number: 11958854
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: April 16, 2024
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF
    Publication number: 20230040259
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Application
    Filed: November 10, 2021
    Publication date: February 9, 2023
    Applicant: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Inhibitors of TRPC6
    Patent number: 11485740
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 1, 2022
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • NOVEL SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20220177479
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 9, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20220056032
    Abstract: The present invention relates to compounds of formula (I) a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Application
    Filed: December 10, 2019
    Publication date: February 24, 2022
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • Substituted xanthines and methods of use thereof
    Patent number: 11208409
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: December 28, 2021
    Assignee: Hydra Biosciences, LLC
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity
    Patent number: 11198696
    Abstract: The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: December 14, 2021
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventor: Kai Gerlach
  • INHIBITORS OF TRPC6
    Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Inhibitors of TRPC6
    Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Substituted xanthines and methods of use thereof
    Patent number: 10399982
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 3, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Substituted xanthine derivatives
    Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10221177
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 5, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9980968
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: May 29, 2018
    Assignee: HYDRA BIOSCIENCES, INC.
    Inventor: Jayhong A. Chong
  • Substituted xanthines and methods of use thereof
    Patent number: 9969736
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 15, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Compounds and compositions for treating chemical warfare agent-induced injuries
    Patent number: 9951073
    Abstract: Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 24, 2018
    Assignee: Hydra Biosciences, Inc.
    Inventor: Jayhong A. Chong
  • METHODS AND COMPOSITIONS FOR TREATING PAIN
    Publication number: 20180093986
    Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.
    Type: Application
    Filed: October 13, 2017
    Publication date: April 5, 2018
    Applicants: Hydra Biosciences, Inc., Hydra Biosciences, Inc.
    Inventors: Magdalene M. Moran, Christopher Fanger, Jayhong A. Chong, Colleen McNamara, Xiaoguang Zhen, Josh Mandel-Brehm
  • Inhibitors of TRPC6
    Patent number: RE49699
    Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu